Takeda to build €100 million dengue vaccine manufacturing plant
pharmafile | December 1, 2016 | News story | Manufacturing and Production, Medical Communications | Takeda, dengue, phase 3
Takeda have announced plans to spend more than €100 million in the construction of a new manufacturing plant in Singen, Germany. Construction on the plant has already begun and Takeda expect the facility to be completed to begin production in 2019.
The decision is a major statement of confidence in its dengue vaccine candidate (TAK-003) that is currently going through Phase 3 clinical trials. The clinical trials began on 7 September, with the clinical trials, named the Tetravalent Immunization against Dengue Efficacy Study (TIDES), enrolling 20,000 children between the ages of four and 16 years of age. The study is double-blind, randomised, placebo-controlled trial of Takeda’s live-attenuated tetravalent dengue vaccine candidate. The aim of the trial is to evaluate the efficacy of the candidate’s protection against symptomatic dengue fever, caused by any of the four dengue virus serotypes and not dependent on whether the individual has been previously exposed to the virus.
Takeda’s move to develop a dengue vaccine comes as 390 million infections occur every year and a resultant 20,000 deaths globally. It is currently the fastest spreading mosquito-borne viral disease.
“This manufacturing plant investment reinforces Takeda’s strong support for our global vaccine strategy in general, and dengue in particular. The new plant will provide millions of people with access to a medicine that addresses a huge unmet medical need. It underlines our commitment to improve the lives of people worldwide,” says Dr Thomas Wozniewski, Global Manufacturing & Supply Officer at Takeda.
Dr. Rajeev Venkayya, president of Takeda Vaccines, added to Dr Wozniewski’s comments by stating that: “This dengue vaccine production facility is another strong indication of Takeda’s long-term commitment to vaccines. The progress of the dengue TIDES clinical trial, our partnership with the Bill & Melinda Gates Foundation to eradicate polio, the recent initiation of the world’s first field efficacy trial for a norovirus vaccine, and our work with the U.S. Government to develop a Zika vaccine, together demonstrate how Takeda is dedicated to developing and providing vaccines to protect people in need wherever they are.”
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
